How Can I Beat the S&P 500? What the Evidence Says
The honest answer to the most asked question in investing: how many people beat the index, why it is so hard, why investors trail even their own funds, and how daily market context fits in.
Revvity, Inc., healthcare (market value $18.2 billion), an S&P 500 member: how it compared with the S&P 500, how it behaved in every crash since 2008, its risk‑adjusted returns and what analysts said. Returns to Oct 30, 2026; analyst data as of Nov 16, 2026.
Exent re-checks this page every day. Ratings appear 30 days after they are published; the top‑ranked analysts’ calls are not counted here, they are in Gems.
What do the best‑ranked analysts on RVTY say now? See it in Exent Gems →
Over the 5 years to Oct 30, 2026, Revvity, Inc. (RVTY) returned −10.2% including dividends, versus +75.9% for the S&P 500 (SPY). It lagged the index by 86.1 percentage points, or −2.1% a year against +12.0%.
| Period | RVTY | S&P 500 | RVTY per year | S&P 500 per year | Result |
|---|---|---|---|---|---|
| 1 year | +68.2% | +12.0% | +68.2% | +12.0% | Beat |
| 3 years | +91.0% | +87.4% | +24.1% | +23.3% | Beat |
| 5 years | −10.2% | +75.9% | −2.1% | +12.0% | Lagged |
| 10 years | +217.3% | +316.3% | +12.2% | +15.3% | Lagged |
Total return with dividends reinvested, from month-end prices to Oct 30, 2026. Beating the index on raw return is only half the story: the next section adjusts for the risk taken. See also how to beat the S&P 500.
RVTY is in the S&P 500 (members as of Oct 20, 2026); the list shows every member’s return against the index.
In the 12 months to 30 days ago, 20 analysts published 118 ratings on RVTY. Their latest calls were 30% Buy, 70% Hold and 0% Sell. 13 of them rank 4★ or higher in Exent’s analyst scoring, which is based on each analyst’s past price‑target hit rate and returns.
The consensus 12‑month price target was $151.43 (range $115.00–$200.00), −0.7% from the last price. Remember that the average analyst’s target is hit only about half the time: how accurate are price targets?
| Top‑ranked analyst covering | Firm | Stars | Price‑target hit rate |
|---|---|---|---|
| ??? | ??? | 5.0★ | 67.1% |
| ??? | ??? | 4.9★ | 59.3% |
| ??? | ??? | 4.9★ | 57.5% |
| Dan Leonard | RBC Capital | 4.8★ | 59.6% |
| Catherine Ramsey Schulte | Robert W. Baird | 4.8★ | 58.0% |
Other analysts covering RVTY: Eve Burstein · Luke Sergott · Vijay Kumar · Daniel Arias · Casey Woodring
Ratings are shown with a 30‑day delay. Who the top‑ranked analysts on RVTY are, their live calls and the median target of only the top‑rated analysts are in Exent Gems.
The average analyst’s target is reached about 53.0% of the time; Exent Gems is built on the top 50 of Exent’s ranking,where some reached 90% or more over the last two years. Unlock the top 50 analysts.
RVTY beat the S&P 500 in 4 of the 9 full calendar years shown.
| Year | RVTY | S&P 500 | Difference |
|---|---|---|---|
| 2026 (to Oct 30, 2026) | +62.7% | +11.7% | +51.0% |
| 2025 | −13.1% | +17.7% | −30.8% |
| 2024 | +2.4% | +24.9% | −22.5% |
| 2023 | −21.9% | +26.2% | −48.1% |
| 2022 | −30.1% | −18.2% | −11.9% |
| 2021 | +40.4% | +28.7% | +11.7% |
| 2020 | +48.2% | +18.3% | +29.9% |
| 2019 | +24.0% | +31.2% | −7.2% |
| 2018 | +7.8% | −4.6% | +12.4% |
| 2017 | +40.8% | +21.7% | +19.1% |
Over 5 years, RVTY had a Sharpe ratio of −0.01 against 0.58 for the S&P 500, so it earned less return per unit of risk than the index. Its annualized volatility was 33.4% and its beta 1.08: it tended to move about 1.1× as much as the market.
| Metric | RVTY | S&P 500 |
|---|---|---|
| Annual return | −2.1% | +12.0% |
| Volatility (annualized) | 33.4% | 15.5% |
| Sharpe ratio | −0.01 | 0.58 |
| Sortino ratio | −0.01 | 0.91 |
| Max drawdown (month-end) | −58.6% | −23.9% |
| Beta to the S&P 500 | 1.08 | 1.00 |
RVTY’s deepest fall in the crises below was −63.0% in the global financial crisis (2007–09), against −56.5% for the S&P 500. The last column turns that into money: what a $100,000 position would have lost from peak to trough.
| Crisis | RVTY | S&P 500 | Loss on $100,000 |
|---|---|---|---|
| Global financial crisis (2007–09) | −63.0% | −56.5% | −$62,950 |
| 2018 trade-war selloff | −26.1% | −20.2% | −$26,110 |
| COVID crash (Feb–Mar 2020) | −29.3% | −34.1% | −$29,280 |
| 2022 inflation bear market | −39.1% | −25.4% | −$39,120 |
| 2025 tariff selloff | −22.4% | −19.0% | −$22,360 |
| Window | RVTY max drawdown |
|---|---|
| Last 1 year | −30.1% |
| Last 3 years | −37.2% |
| Last 5 years | −59.0% |
| Last 10 years | −59.2% |
Peak‑to‑trough declines from daily prices inside each crisis window. A crash replay does not predict the next crisis; it shows how much room a holding needs. Run the same replay on a whole portfolio with the crash test.
Correlation runs from −1 (moves opposite) to +1 (moves in lockstep). Over the last 60 months of monthly returns, RVTY’s correlation with the S&P 500 was 0.50, with the Nasdaq‑100 0.42, with long Treasuries (TLT) 0.42 and with gold (GLD) 0.11.
Adding a 5% RVTY position to an S&P 500 portfolio would have moved its 5‑year volatility from 15.5% to 15.6%.
| Least correlated large caps | Correlation | Most correlated large caps | Correlation |
|---|---|---|---|
| CME | −0.07 | TMO | 0.68 |
| PGR | −0.06 | DHR | 0.66 |
| WM | −0.03 | MMM | 0.52 |
| PLTR | −0.01 | HCA | 0.49 |
| COP | −0.01 | MRNA | 0.47 |
Holdings that are highly correlated behave like one position in a selloff. See how to find hidden overlap.
| Date | Rating and target | Analyst |
|---|---|---|
| Nov 16 | Target raised Hold | Casey Woodring |
| Nov 12 | Target raised Hold | Eve Burstein |
| Nov 4 | Target raised Buy | Catherine Ramsey Schulte |
| Nov 4 | Target raised Hold | Luke Sergott |
| Nov 4 | Target raised Hold | Daniel Arias |
| Nov 4 | Target raised Hold | Casey Woodring |
| Nov 3 | Target raised Buy | Vijay Kumar |
| Nov 3 | Target raised Hold | Dan Leonard |
| Oct 16 | Target raised Hold | Casey Woodring |
| Oct 7 | Target raised Hold | Luke Sergott |
| Oct 5 | New coverage Buy | Matt Larew |
| Sep 20 | Target raised Hold | Evie Koslosky |
Named analysts’ rating and price‑target changes on RVTY in the 5 weeks to Oct 20, 2026, shown 30 days after publication (the free analysts’ calls 3 days after). The top‑ranked analysts’ calls are in Exent Gems. See all of the latest analyst upgrades and downgrades.
Of the 219 analyst price targets on RVTY set from 2019 until a year ago, 54.3% were reached within 12 months (data to Oct 20, 2026), 14.3 points below the 68.6% hit rate of the median stock in Exent’s study of 794 stocks. Targets that were reached took a median of 63 days. The median target sat 12.8% above the share price on the day it was set.
Where analysts said RVTY would be by now: a year ago, 7 analysts had a price target on RVTY, and the median of their latest targets was $106.00. On Oct 20, 2026 RVTY closed at $156.03, 47.2% above it.
| After | Calls | Move on the call | 3 months vs S&P 500 |
|---|---|---|---|
| Upgrades of RVTY | 12 | +0.3% | −8.3% |
| Upgrades, all stocks | 11,514 | +2.5% | +3.4% |
| Downgrades of RVTY | 8 | −1.7% | −7.3% |
| Downgrades, all stocks | 10,700 | −3.0% | −1.6% |
The move on the call runs from the close before the rating change to the close after it; the last column is the stock’s return minus the S&P 500’s over the next three months. Averages of rating changes on RVTY through Sep 15, 2026; analysts are not named here. Do analyst upgrades move stocks?
RVTY beat the consensus earnings‑per‑share estimate in 11 of its last 12 quarterly reports, through the one on Aug 4, 2026, and the revenue estimate in 9 of 12. From the close before each report to the close after it, the stock moved 5.7% on average, up or down, against 6.8% for the average report across the 1,002 US stocks Exent tracks. It rose after 5 of the 12 reports. In 6 of the 11 beats the stock still fell.
| Report | EPS vs estimate | Revenue vs estimate | Stock move |
|---|---|---|---|
| Aug 4, 2026 | $1.41 vs $1.21 | +1.1% | −0.2% |
| May 5, 2026 | $1.06 vs $1.02 | +1.0% | +14.5% |
| Feb 2, 2026 | $1.70 vs $1.57 | +0.9% | −7.1% |
| Oct 27, 2025 | $1.18 vs $1.14 | −0.1% | −2.5% |
| Jul 28, 2025 | $1.18 vs $1.14 | +2.9% | −8.9% |
| Apr 28, 2025 | $1.01 vs $0.96 | −6.5% | +0.4% |
| Jan 31, 2025 | $1.42 vs $1.37 | +9.6% | −2.5% |
| Nov 4, 2024 | $1.28 vs $1.13 | +0.6% | +4.1% |
Reported earnings per share against the consensus estimate, revenue surprise in percent, and the stock’s price change over the two sessions around the report. How stocks move after earnings
In fiscal 2025 (the year to Dec 28, 2025), 9.3% of RVTY’s $4.6 billion revenue came from China, down from 10.2% in fiscal 2024. By region: Other International 59.5%; United States 24.6%; China 9.3%; Germany 3.9%.
By business, the largest segment was Life Sciences, with 50.1% of $2.9 billion revenue (+14.1% on the year before).
| Segment | Revenue | Share | Growth |
|---|---|---|---|
| Life Sciences | $1.4 billion | 50.1% | +14.1% |
| Diagnostics | $1.4 billion | 49.9% | −5.1% |
From RVTY’s annual filings; segment growth compares fiscal 2025 with the year before. Regions are as each company reports them, so one company’s “Asia Pacific” is not another’s. China counts the regions a company reports as China, Greater China or Hong Kong; a separately reported Taiwan is not counted. Which S&P 500 companies depend most on China?
As of Oct 20, 2026, 5 members of Congress had disclosed 29 trades in RVTY (19 buys and 10 sales) in STOCK Act disclosures filed with the House and Senate. The latest public trade is dated May 4, 2026.
| Trade date | Member | Type | Amount |
|---|---|---|---|
| May 4, 2026 | Gilbert Cisneros | Buy | $15,001–$50,000 |
| May 1, 2026 | Gilbert Cisneros | Buy | $1,001–$15,000 |
| Sep 29, 2025 | Ro Khanna | Buy | $1,001–$15,000 |
| Sep 12, 2025 | Gilbert Cisneros | Buy | $1,001–$15,000 |
| Aug 26, 2025 | Ro Khanna | Sale | $1,001–$15,000 |
| Aug 13, 2025 | Gilbert Cisneros | Buy | $1,001–$15,000 |
| Jul 23, 2025 | Gilbert Cisneros | Buy | $1,001–$15,000 |
| Jul 22, 2025 | Lisa McClain | Sale | $1,001–$15,000 |
| Jun 17, 2025 | Lisa McClain | Buy | $1,001–$15,000 |
| Jun 11, 2025 | Gilbert Cisneros | Buy | $1,001–$15,000 |
Amounts are the ranges members report, not exact values. The STOCK Act gives members up to 45 days to disclose a trade, so trades appear weeks after they are made. See every member’s disclosed trades
3 trades in RVTY disclosed in the last 30 days are in Exent Radar.
In the 12 months to Oct 20, 2026, RVTY insiders made no open‑market purchases and 17 sales worth $6.0 million, according to SEC Form 4 filings.
The chart counts Form 4 purchases and sales by calendar quarter. Purchases are open‑market buys; sales include planned sales under 10b5‑1 trading plans. Do insider buys beat the market?
As of the Sep 30, 2026 settlement date, 6.15% of RVTY’s float was sold short: 6.3 million shares, or 2.4 days of average trading volume to cover. A year earlier (Oct 15, 2025) it was 7.87%. The median across the 997 US stocks Exent tracks was 4.77%, so RVTY is more heavily shorted than most.
From FINRA short‑interest reports, filed twice a month; the bars show the short share of the float at each month‑end. Days to cover divides the shares short by the average daily volume. The most shorted stocks
At the end of Q2 2026 (Jun 30, 2026), 555 institutions reported holding RVTY in 13F filings, up 42 from the quarter before and up from 546 a year earlier. Their reported holdings add up to 103.0% of RVTY’s shares. In the quarter 300 institutions added to their positions and 167 cut them.
Investment managers with over $100 million in US equities file 13F reports within 45 days of each quarter end, so this is the latest complete quarter. Holdings can add up to more than 100% when shares are lent and counted twice. Which stocks institutions are buying and selling
RVTY’s diluted share count rose 1.0% over the five fiscal years to fiscal 2025 and fell 7.8% in fiscal 2025 alone. Each share now owns a smaller slice of the company. The median change across the 1,005 US stocks Exent tracks was −0.1%.
Stock‑based compensation was $22.8 million in fiscal 2025, 0.8% of revenue. RVTY spent $820.8 million buying back shares, a buyback yield of 5.71% of its market value; stock pay equaled 2.8% of the buybacks.
Weighted‑average diluted shares from RVTY’s annual income statements; stock‑based compensation and buybacks from its cash‑flow statement. Stock dilution and stock‑based compensation, explained
In Exent’s Oct 20, 2026 snapshot, RVTY’s Altman Z‑score was 3.28, in the safe zone (where 465 of the 794 non‑financial US stocks Exent tracks sit). Its Piotroski F‑score was 8 out of 9; 20% of scored stocks reach 8 or more.
The Altman Z‑score combines five balance‑sheet and earnings ratios into one bankruptcy‑risk score: below 1.81 is the distress zone, 1.81–2.99 grey, above 2.99 safe. It is not meaningful for banks, insurers and REITs. The Piotroski F‑score counts nine yes/no tests of profitability, leverage and efficiency; 8–9 is strong, 0–2 weak. Both come from the latest annual statements. Which stocks have the highest bankruptcy risk?
On its latest earnings call (Aug 6, 2026), RVTY’s executives and analysts mentioned AI 40 times, against 26 on the call before (May 5, 2026); the average across 455 S&P 500 calls that quarter was 12.9. After AI, the most mentioned topic was tariffs (14).
| Mentions | Aug ’26 | May ’26 | Feb ’26 | Oct ’25 |
|---|---|---|---|---|
| AI | 40 | 26 | 11 | 29 |
| AI agents | 0 | 0 | 0 | 2 |
| Data centers | 0 | 0 | 0 | 0 |
| Tariffs | 14 | 1 | 6 | 5 |
| China | 8 | 35 | 13 | 36 |
| Recession | 0 | 0 | 0 | 0 |
Word counts in the full transcript of each call, prepared remarks and Q&A, newest first. “AI” also counts generative AI and large language models; “AI agents” counts agentic AI. Which companies talk most about AI?
As of Oct 20, 2026, 42 of the 304 ETFs Exent tracks held RVTY. Its largest weight is in DFAT (Dimensional U.S. Targeted Value ETF), at 0.49% of the fund.
| ETF | Fund | Weight of RVTY |
|---|---|---|
| DFAT | Dimensional U.S. Targeted Value ETF | 0.49% |
| VBR | Vanguard Small-Cap Value Index Fund ETF Shares | 0.39% |
| SCHM | Schwab U.S. Mid-Cap ETF | 0.35% |
| XLV | State Street Health Care Select Sector SPDR ETF | 0.26% |
| RSP | Invesco S&P 500 Equal Weight ETF | 0.24% |
| VHT | Vanguard Health Care Index Fund ETF Shares | 0.24% |
| DFSV | Dimensional US Small Cap Value ETF | 0.23% |
| VB | Vanguard Small-Cap Index Fund ETF Shares | 0.22% |
Owning several of these funds stacks the same position. How much do VOO, QQQ and VTI overlap?
Exent matches every holding to the index with the most similar risk. For RVTY that is MDY. Comparing a holding with an index that carries very different risk makes good results look bad and risky ones look clever. Read why the S&P 500 is the wrong benchmark for most portfolios.
| Ticker | Name | 5‑year return | Volatility (5y) |
|---|---|---|---|
| LLY | Eli Lilly and Company | +482.3% | 32.6% |
| JNJ | Johnson & Johnson | +92.9% | 16.8% |
| ABBV | AbbVie Inc. | +207.1% | 23.5% |
| EXEL | Exelixis, Inc. | +222.6% | 35.4% |
| ZBH | Zimmer Biomet Holdings, Inc. | −28.8% | 26.9% |
| NBIX | Neurocrine Biosciences, Inc. | +38.6% | 33.0% |
| MEDP | Medpace Holdings, Inc. | +187.8% | 49.2% |
| CRL | Charles River Laboratories International, Inc. | −19.9% | 44.7% |
Returns are total returns from month‑end adjusted closing prices (dividends reinvested) through Oct 30, 2026. Crisis drawdowns and trailing maximum drawdowns use daily prices. Analyst coverage counts ratings published in the last 12 months, shown with a 30‑day delay. Full method: Exent methodology.
Company data as of Oct 20, 2026. The move around an earnings report runs from the close before it to the close after it; a price target counts as hit when the stock closed at or beyond it within 12 months (Exent analyst data). Revenue by region and segment, share counts and executive pay come from company filings; insider trades from SEC Form 4, short interest from FINRA, institutional ownership from 13F filings, Congress trades from STOCK Act disclosures filed with the House and Senate, federal contracts from USAspending.gov. Filings from the last 30 days are shown as counts only.
Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.
Wall Street’s average RVTY price target is 0.7% below the latest share price. See what the best‑ranked analysts on RVTY say now in Exent Gems.
No. RVTY returned +217.3% (+12.2% a year) over the 10 years to Oct 30, 2026, versus +316.3% (+15.3% a year) for the S&P 500, including dividends.
Yes. As of Oct 20, 2026, RVTY (Revvity, Inc.) is one of the 503 stocks in the S&P 500.
RVTY fell −63.0% from peak to trough during the global financial crisis (2007–09), versus −56.5% for the S&P 500.
RVTY fell −29.3% from peak to trough during the covid crash (feb–mar 2020), versus −34.1% for the S&P 500.
RVTY fell −39.1% from peak to trough during the 2022 inflation bear market, versus −25.4% for the S&P 500.
Over the 5 years to Oct 30, 2026, RVTY’s Sharpe ratio was −0.01 and its Sortino ratio −0.01, versus 0.58 and 0.91 for the S&P 500.
RVTY’s 5‑year annualized volatility was 33.9%, higher than the S&P 500’s 17.0%, with a beta of 1.08.
Among large US stocks, the lowest correlations with RVTY over the last 60 months were CME (−0.07), PGR (−0.06), WM (−0.03). Its correlation with long Treasuries (TLT) was 0.42 and with gold (GLD) 0.11.
RVTY beat the consensus earnings-per-share estimate in 11 of its last 12 quarterly reports through Aug 4, 2026, and the revenue estimate in 9 of 12. The stock moved 5.7% on average, up or down, from the close before each report to the close after it.
In fiscal 2025 (the year to Dec 28, 2025), 9.3% of RVTY’s $4.6 billion revenue came from China, about $426.5 million, down from 10.2% in fiscal 2024. Regions are as RVTY reports them in its annual filings.
Yes. As of Oct 20, 2026, 5 members of Congress had disclosed 29 trades in RVTY (19 buys and 10 sales) in STOCK Act disclosures filed with the House and Senate.
As of the Sep 30, 2026 settlement date, 6.15% of RVTY’s float was sold short (6.3 million shares, 2.4 days to cover), according to FINRA short-interest reports. A year earlier it was 7.87%.
Yes. RVTY’s diluted share count rose 1.0% over the five fiscal years to fiscal 2025 and fell 7.8% in the latest year. Stock-based compensation was 0.8% of revenue, and buybacks totaled $820.8 million.
Exent ranks Wall Street analysts by their track record. Gems shows who the top‑ranked analysts on RVTY are, their latest calls and the stocks where several of them agree.
Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.